Skip to main content

Building Related Illness (BRI)/ Sick Building Syndrome (SBS)

BayBiotech.NET
Built environments both residential and non residential are subject to number of indoor air quality (IAQ) and Indoor environment (IE) problems that may cause acute symptoms, health risks or discomfort.
A frequent IAQ and IE investigations can determine the occurrence of BRI and provide with healthier work environment. This is of utmost importance for Pharmaceutical/ Life Sciences industry where the product is directly subject to the human usage.
Non residential buildings are more prone to BRI as there is a high volume of occupants coming from diverse geographical areas interact in an environment where the ventilation of the building is not directly under the occupants control.
Health hazard evaluation teams from the National Institute of Occupational Safety and Health (NIOSH) conducts the investigation upon request and provides with strategies to avoid the recurrence of the problem. Some of the risk factors that may be used to evaluate biological contaminants as potential causes of allergy/asthma/sinusitis are as follows:
1. Mold: active mold infestation on building material, building history of water damage, wet building site, musty odors, viable mold test results of >1000 CFU/m3 and total mold counts >10,000 S/m3.
2. Dust mites: damp interiors, > 2 ug/g mite allergen levels in floor dust samples.
3. Apart from dust mites and mold, bacterias are major contributors to indoor health hazards and some of the diseases caused due to them are Tuberculosis, Pneumonia, Diphtheria, Anthrax, Meningitis, Respiratory infections and wound infections.

Poor IAQ contributed by various identifiable factors may cause decreased work performance and may impose significant economic costs on employers. Thus, it is important to have a regular investigations planned to test the health of the buildings used for performing the work.

In the US, NIOSH has developed a protocol to serve the needs of its health hazard evaluation teams. Such a team consists of an industrial hygienist, an epidemiologist, and a technical person familiar with the operation and maintenance of building mechanical systems.

To find out more on the topic, you may want to follow the readings as under:

1. www.epa.gov
2. USEPA/ NIOSH, EPA/400/1-91/003, DHHS Publication No. 91-1141-1991.
3. Thad Godish, Indoor Environmental Quality, CRC Press LLC, 2001.

Comments

Popular posts from this blog

ISO Management Standards for Medical Devices

Two main ISO standards that have a direct application to Medical Device Industry are ISO 9001 and ISO 13485. While ISO 9001 is for evolving a Quality Management System for an organization, ISO 13485 has a direct application to Medical Device Industry. Although, ISO standards for a company are not a legal requirement, but provide a validation and ease of global marketing of the product.

eCTD Submission Specifications

BayBiotech.NET The electronic Common Technical Document (eCTD) is an interface for the pharmaceutical industry to agency transfer of regulatory information. eCTD technical document format development was done by International Conference on Harmonization (ICH) Multidisciplinary Group 2 Expert Working Group (ICH M2 EWG). Details on the specification for the ICH eCTD can be found in the guidance document M2 eCTD: Electronic Common Technical Document Specification. Currently, eCTD is the preferred format for electronic submissions by U.S. Food and Drug Administration. Although originally the CTD and the eCTD were designed for marketing applications, they could apply equally to other submission types, including INDs, master files, advertising material, and promotional labeling. In June 2008, FDA has issued guidelines for organizing the electronic regulatory document filing using the eCTD tools. This guidance discusses issues related to the electronic submission of applications for hum

FDA Launches Medical Device and Radiation-Emitting Product Transparency Web Site

BayBiotech.NET On April 19th, 2010 FDA launched he Center for Devices and Radiological Health (CDRH) Transparency Web site in support of the agency’s Transparency Initiative. The Web site makes available new information about CDRH’s decision-making processes and displays this information in a more user-friendly format. The site includes new information such as basic information about medical devices and how FDA regulates those products, information about medical devices before and after the products are on the market, in a searchable database, information about the clinical studies and trials conducted to demonstrate the safety and effectiveness of certain medical devices, memos from FDA employees explaining the reasons for the agency's decisions about medical device manufacturer requests to make a significant change in components, materials, design, specification, software, color additive, and labeling of a medical device as well as a step-by-step guide for manufacturers of